Changes in cytokine levels in the blood of eczema patients with complex treatment with upadacitinib

Objective: to study changes in immunological parameters in patients with true eczema during complex therapy with the use of upadacitinib. Materials and methods. The work was performed with the participation of 131 patients aged 18 to 70 years (average age 58.7±3.6 years) with a diagnosis of true eczema, who were on inpatient treatment. The patients were divided into 4 groups: the first group received basic drug therapy (BMT), the second - phototherapy (FT) and BMT (BMT+FT), the third - upadacitinib (UPA) and BMT (BMT+ UPA), the fourth - BMT+FT+UPA. The content of IL-1ß, IL-2, IL-6, IL-10, INF-γ, TNF-α in the blood serum of patients was determined by enzyme immunoassay before the start of treatment and 2 and 4 months after its start. Results. Before the start of treatment, the values of IL-1ß, IL-2, IL-6, IL-10, INF-γ, TNF-α in the blood serum of patients in comparison with healthy individuals were significantly increased (3.7-4.2 times) against the background of a decrease in the level of IL-10 (2 times). In patients of the first group, the cytokine level did not change significantly after 2 and 4 months from the start of treatment in comparison with the indicators before the start of treatment. In the second group, at all follow-up periods, the content of IL-10 significantly increased with a decrease in the levels of IL-1ß, IL-2 and IL-6. When using UPA in the third group, the content of IL-10 increased against the background of a marked decrease in all other cytokines studied. The greatest changes were noted in the fourth group during the complex treatment of UPA with FT and BMT: a significantly significant decrease in the levels of IL-1, IL-2, IL-6, INF-γ, TNF-α (by 53-67%, p<0.001) against the background of an increase in the content of IL-10 (by 69%, p<0.001). The preservation of the orientation and severity of the identified shifts after 4 months indicates their stability. Conclusion. In patients with true eczema, the use of upadacitinib as part of complex treatment in combination with basic drug therapy and phototherapy causes a pronounced and prolonged correction of the cytokine profile in the blood.

1. Makhulayeva A.M. Results of complex treatment of patients with varicose eczema of the lower leg associated with mycotic infection. Al’manakh klinicheskoy meditsiny. 2010;(10):219-224 (in Russ.). EDN: HZOWZV.

2. Cazzaniga S., Ballmer-Weber B.K., Gräni N., Spring P., Bircher A., Anliker M., Sonntag A.K., Piletta P., et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol. 2016;30(4):628-637. DOI: 10.1111/jdv.13479.

3. Nikonovа I.V., Orlov E.V., Konnov P.E. Condition of biocenosis skin at microbial eczema. Prakticheskaya meditsina. 2011;2(49):80-83 (in Russ.). EDN: NUBVJZ.

4. Sohn A., Frankel A., Patel R.V., Goldenberg G. Eczema. Mt Sinai J Med. 2011;78(5):730-739. DOI: 10.1002/msj.20289.

5. Andrashko Y.V., Khwaileh M.K. Specifics of the eczema patients` immune system depending on the clinical course of dermatosis. Wiad Lek. 2021;74(10 cz 2):2624-2626.

6. Ugaĭ V.G., Udzhukhu V.Iu., Potekaev N.N. Novel approaches to immunomodulating therapy of the patients presenting with nummular eczema.Russian journal of clinical dermatology and venereology. 2011;9(4):42-45 (in Russ.). EDN: QAAPCV.

7. Banerjee S., Biehl A., Gadina M., Hasni S., Schwartz D.M. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77(5):521-546. DOI: 10.1007/s40265-017-0701-9.

8. Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O'Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862. DOI: 10.1038/nrd.2017.201.

9. Virtanen A.T., Haikarainen T., Raivola J., Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. DOI: 10.1007/s40259-019-00333-w.

10. Damsky W., King B.A. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-744. DOI: 10.1016/j.jaad.2016.12.005.

11. McInnes I.B., Anderson J.K., Magrey M., Merola J.F., Liu Y., Kishimoto M., Jeka S., Pacheco-Tena C., et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227-1239. DOI: 10.1056/NEJMoa2022516.

12. Shreberk-Hassidim R., Ramot Y., Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017;76(4):745-753.e19. DOI: 10.1016/j.jaad.2016.12.004.

13. Register of medicines of Russia: instructions for the medical use of the drug Rinvoq (in Russ.). URL: https://www.rlsnet.ru/active-substance/upadacitinib-3942

14. Eczema. Clinical recommendations (in Russ.). URL: https://cr.minzdrav.gov.ru/recomend/246_2

15. Sherengovskaya Yu.V., Gorlova N.A., Prokhorov D.V., Kuznetsova M.Yu., Gromova A.V. The role of interleukins in evaluating the effectiveness of spa treatment of patients with eczema. Vestnik fizioterapii i kurortologii. 2020;6(1):88 (in Russ.). EDN: TEWWYB.

16. Bolotnaya L.A., Kalashnikova V.S. The role of cytokines in the pathogenesis of chronic eczema. Dermatovenerologiya. Kosmetologiya. Seksopatologiya. 2007;1-4(10):86-88 (in Russ.)

17. Hart P.H., Norval M. More Than Effects in Skin: Ultraviolet Radiation-Induced Changes in Immune Cells in Human Blood. Front Immunol. 2021;12:694086. DOI: 10.3389/fimmu.2021.694086.

18. Hart P.H., Norval M., Byrne S.N., Rhodes L.E. Exposure to Ultraviolet Radiation in the Modulation of Human Diseases. Annu Rev Pathol. 2019;14:55-81. DOI: 10.1146/annurev-pathmechdis-012418-012809.

19. Alipov N.V., Bakulev A.L.Comparative evaluation of the influence of long long-wave and narrow-band medium-wave UV-therapy on cytokine profile and endotelin-1 in children of patients with atopic dermatitis. Fizioterapevt. 2017;(6):10-15 (in Russ.). EDN: YAKLKH.